Mengis Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mengis Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,095	Closed	-$722K	–	123
2018 Q2	$722K	Sell	2,095 -40	-2%	-$12.5K	0.43%	68
2018 Q1	$735K	Sell	2,135 -30	-1%	-$10.4K	0.44%	68
2017 Q4	$813K	Sell	2,165 -80	-4%	-$32.4K	0.49%	60
2017 Q3	$1M	Buy	2,245 +20	+0.9%	+$9.52K	0.67%	46
2017 Q2	$1.09M	Buy	2,225 +705	+46%	+$309K	0.77%	40
2017 Q1	$589K	Buy	+1,520	New	+$563K	0.43%	68

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Mengis Capital Management's REGN Position: Q3 2018 in Review

Mengis Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 2,095 shares — an estimated $722K sold.

Mengis Capital Management first reported a position in REGN in Q1 2017 and held it in 6 quarters. The position peaked at $1.09M in Q2 2017. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

Mengis Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Mengis Capital Management sold 2,095 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $722K.
Mengis Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Mengis Capital Management's Regeneron Pharmaceuticals position peaked at $1.09M in Q2 2017.
644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Mengis Capital Management's 13F filing for Q3 2018, filed 5 Nov 2018.